Status:
COMPLETED
Methylphenidate and Parkinson's Disease
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Parkinson's Disease
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodo...
Detailed Description
Parkinson's disease (PD) is a common disorder caused by the loss of dopamine-producing brain cells. The disorder is generally treated with levodopa combined with carbidopa. Nerve cells use levodopa to...
Eligibility Criteria
Inclusion
- Idiopathic PD treated with levodopa and experiencing motor fluctuations
- At least 21 years of age
- Male or female.
Exclusion
- Cardiovascular disease, psychosis, extreme anxiety, dementia and other unstable medical conditions.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00359723
Start Date
July 1 2004
End Date
March 1 2006
Last Update
November 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, OP-2, Oregon Health & Science University, 3181 SW Sam Jackson Park Road
Portland, Oregon, United States, 97239